{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "e7369e59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a828cac2ffd84b3fb5533ee34c68b93f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading weights:   0%|          | 0/103 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[1mBertModel LOAD REPORT\u001b[0m from: sentence-transformers/all-MiniLM-L6-v2\n",
      "Key                     | Status     |  | \n",
      "------------------------+------------+--+-\n",
      "embeddings.position_ids | UNEXPECTED |  | \n",
      "\n",
      "\u001b[3mNotes:\n",
      "- UNEXPECTED\u001b[3m\t:can be ignored when loading from different task/architecture; not ok if you expect identical arch.\u001b[0m\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.api_core once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.api_core past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.resourcemanager_v3 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.resourcemanager_v3 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.instance_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.instance_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.params_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.params_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.predict.prediction_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.predict.prediction_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1.schema.trainingjob.definition_v1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1.schema.trainingjob.definition_v1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.instance_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.instance_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.params_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.params_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.predict.prediction_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.predict.prediction_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/google/api_core/_python_version_support.py:275: FutureWarning: You are using a Python version (3.10.12) which Google will stop supporting in new releases of google.cloud.aiplatform.v1beta1.schema.trainingjob.definition_v1beta1 once it reaches its end of life (2026-10-04). Please upgrade to the latest Python version, or at least Python 3.11, to continue receiving updates for google.cloud.aiplatform.v1beta1.schema.trainingjob.definition_v1beta1 past that date.\n",
      "  warnings.warn(message, FutureWarning)\n",
      "/home/ixti95/Clinical-Trial-Protocol-Design-Support/venv/lib/python3.10/site-packages/vertexai/generative_models/_generative_models.py:433: UserWarning: This feature is deprecated as of June 24, 2025 and will be removed on June 24, 2026. For details, see https://cloud.google.com/vertex-ai/generative-ai/docs/deprecations/genai-vertexai-sdk.\n",
      "  warning_logs.show_deprecation_warning()\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import sys\n",
    "import torch\n",
    "\n",
    "# Add src directory to path\n",
    "sys.path.insert(0, os.path.abspath('../src'))\n",
    "\n",
    "from parser import process_pdf\n",
    "from section_splitter import split_into_sections\n",
    "from section_classifier import embed, TARGET_QUERIES\n",
    "from agents import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0a3d74ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "parsed_data = process_pdf('../data/protocol.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "24bbd96b",
   "metadata": {},
   "outputs": [],
   "source": [
    "sections = split_into_sections(parsed_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "a41f1781",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _top_sections_for_target(sections, target, num_sections=2):\n",
    "    section_titles = list(sections.keys())\n",
    "    section_embeddings = embed(list(sections.keys()))\n",
    "\n",
    "    query_embedding = embed([TARGET_QUERIES[target]])[0]\n",
    "    scores = torch.matmul(section_embeddings, query_embedding)\n",
    "\n",
    "    top_scores, top_indices = torch.topk(scores, k=min(num_sections, len(section_titles)))\n",
    "\n",
    "    results = []\n",
    "    for score, idx in zip(top_scores.tolist(), top_indices.tolist()):\n",
    "        results.append((section_titles[idx], score))\n",
    "\n",
    "    return results\n",
    "\n",
    "\n",
    "def run_objectives_extraction(sections, num_sections=2):\n",
    "    \"\"\"\n",
    "    Extract objectives/endpoints without enforced structure.\n",
    "    \"\"\"\n",
    "    top_sections = _top_sections_for_target(sections, \"objectives and endpoints\", num_sections=num_sections)\n",
    "\n",
    "    print(\"objectives -> \" + \", \".join([f\"{title} (score={score:.3f})\" for title, score in top_sections]))\n",
    "\n",
    "    combined_content = \"\\n\\n\".join([sections[title] for title, _ in top_sections])\n",
    "\n",
    "    return extract_objectives(combined_content)\n",
    "\n",
    "\n",
    "def run_eligibility_extraction(sections, num_sections=2):\n",
    "    \"\"\"\n",
    "    Extract eligibility criteria without enforced structure.\n",
    "    \"\"\"\n",
    "    top_sections = _top_sections_for_target(sections, \"eligibility\", num_sections=num_sections)\n",
    "\n",
    "    print(\"eligibility -> \" + \", \".join([f\"{title} (score={score:.3f})\" for title, score in top_sections]))\n",
    "\n",
    "    combined_content = \"\\n\\n\".join([sections[title] for title, _ in top_sections])\n",
    "\n",
    "    return extract_eligibility(combined_content)\n",
    "\n",
    "def run_soa_extraction(sections, num_sections=2):\n",
    "    \"\"\"\n",
    "    Extract schedule of activities without enforced structure.\n",
    "    \"\"\"\n",
    "    top_sections = _top_sections_for_target(sections, \"schedule of activities\", num_sections=num_sections)\n",
    "\n",
    "    print(\"schedule of activities -> \" + \", \".join([f\"{title} (score={score:.3f})\" for title, score in top_sections]))\n",
    "\n",
    "    combined_content = \"\\n\\n\".join([sections[title] for title, _ in top_sections])\n",
    "    \n",
    "    return extract_soa(combined_content)\n",
    "\n",
    "def run_visit_definitions_extraction(sections, num_sections=2):\n",
    "    \"\"\"\n",
    "    Extract visit definitions and timing without enforced structure.\n",
    "    \"\"\"\n",
    "    top_sections = _top_sections_for_target(sections, \"visit_definitions\", num_sections=num_sections)\n",
    "\n",
    "    print(\"visit definitions -> \" + \", \".join([f\"{title} (score={score:.3f})\" for title, score in top_sections]))\n",
    "\n",
    "    combined_content = \"\\n\\n\".join([sections[title] for title, _ in top_sections])\n",
    "    \n",
    "    return extract_visit_definitions(combined_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "3188f1f8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "objectives -> OBJECTIVES   AND ENDPOINTS (score=0.571), STUDY  DESIGN: Scientific Rationale for Study Design: Rationale for Study Design and Participant Population, Rationale for Study Endpoints\n",
      "The efficacy endpoints in this study are analogous to endpoints used for evaluating the (score=0.561)\n",
      "eligibility -> STUDY  POPULATION: Inclusion Criteria\n",
      "Participants are eligible to be included inthe study only if all of the following criteria apply:\n",
      "Age (score=0.803), STUDY  POPULATION: Exclusion Criteria\n",
      "Participants are excluded from the study if any of the following criteria apply:\n",
      "Medical Conditions\n",
      "1  History of allergy to any component of the vaccine (score=0.620)\n",
      "schedule of activities -> PROTOCOL   SUMMARY: Schedule of Activities\n",
      "The SoA tables include: (score=0.483), STUDY  ASSESSMENTS   AND  PROCEDURES: Medical Resource Utilization and Health Economics (score=0.477)\n",
      "visit definitions -> STUDY  ASSESSMENTS   AND  PROCEDURES: Safety Assessments: Physical Examinations\n",
      "A complete physical examination will be performed at screening followed bytargeted, Vital Signs, Clinical Laboratory Assessments (score=0.433), STUDY  ASSESSMENTS   AND  PROCEDURES: Efficacy Assessments: Monitoring COVID-19 Symptoms, Illness Visits, SARS-CoV-2 Testing and Other Virology Assessments, Digital Health Device, Illness e-Diary\n",
      "An Illness e-Diary will be used to collect self-reported information about COVID-19-, Severe COVID-19, Medical Notes Review, Monitoring for Asymptomatic Infection (score=0.395)\n"
     ]
    }
   ],
   "source": [
    "objectives_output = run_objectives_extraction(sections, num_sections=2)\n",
    "eligibility_output = run_eligibility_extraction(sections, num_sections=2)\n",
    "soa_output = run_soa_extraction(sections, num_sections=2)\n",
    "visit_definitions_output = run_visit_definitions_extraction(sections, num_sections=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "8ff96821",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "```json\n",
      "{\n",
      "  \"inclusion_criteria\": [\n",
      "    \"Adult, ≥ 18 years of age at thetime of consent\",\n",
      "    \"Increased risk of SARS-CoV-2 infection\\n    Defined as adults whose locations or circumstances put them at appreciable risk of\\n     exposure to SARS-CoV-2 and COVID-19, based on available risk assessment\\n     contemporaneous to enrollment (believed to be at risk/exposure)\",\n",
      "    \"Medically stable such that, according to the judgment of the investigator, hospitalization\\n   within the study period is not anticipated and the participant appears likely to be able to\\n   remain on study through the end of protocol-specified follow-up\\n    A stable medical condition is defined as disease not requiring significant change in\\n     therapy or hospitalization for worsening disease during the 3 months prior to\\n     enrollment\",\n",
      "    \"Able to understand and comply with study requirements/procedures (if applicable, with\\n   assistance by caregiver, surrogate, or legally authorized representative) based on the\\n   assessment of the investigator\",\n",
      "    \"Contraceptive use by women should be consistent with local regulations regarding the\\n   methods of contraception for those participating in clinical studies\",\n",
      "    \"Female participants\\n   (a) Women of childbearing potential must:\\n        Have a negative pregnancy test on the day of screening and on Day 1\\n        Use one highly effective form of birth control for at least 28 days prior to Day 1\\n         and agree to continue using one highly effective form of birth control through\\n         60 days following administration of the second dose of study intervention.\\n         A highly effective method of contraception is defined as one that can achieve a\\n         failure rate of less than 1% per year when used consistently and correctly (see\\n         Table 6). Periodic abstinence, the rhythm method, and withdrawal are NOT\\n         acceptable methods of contraception.\",\n",
      "    \"Women are considered of childbearing potential unless they meet either of the\\n      following criteria:\\n        Surgically sterilized (including bilateral tubal ligation, bilateral oophorectomy, or\\n         hysterectomy), or\\n        Post-menopausal\\n           For women aged < 50 years, post-menopausal is defined as having both:\\n            o  A history of ≥ 12 months amenorrhea prior to randomization, without\\n               an alternative cause, following cessation of exogenous sex-hormonal\\n               treatment, and\\n            o  A follicle-stimulating hormone level in the post-menopausal range\\n            Until follicle-stimulating hormone is documented to be within menopausal\\n            range, the participant is to be considered of childbearing potential\\n           For women aged ≥ 50 years, post-menopausal is defined as having a history\\n            of ≥ 12 months amenorrhea prior to randomization, without an alternative\\n            cause, following cessation of exogenous sex-hormonal treatment\",\n",
      "    \"Capable of giving signed informed consent as described in Appendix A, which includes\\n   compliance with the requirements and restrictions listed in the ICF and in this protocol\",\n",
      "    \"Adult, ≥ 18 years of age at thetime of consent\",\n",
      "    \"Increased risk of SARS-CoV-2 infection\\n    Defined as adults whose locations or circumstances put them at appreciable risk of\\n     exposure to SARS-CoV-2 and COVID-19, based on available risk assessment\\n     contemporaneous to enrollment (believed to be at risk/exposure)\",\n",
      "    \"Medically stable such that, according to the judgment of the investigator, hospitalization\\n   within the study period is not anticipated and the participant appears likely to be able to\\n   remain on study through the end of protocol-specified follow-up\\n    A stable medical condition is defined as disease not requiring significant change in\\n     therapy or hospitalization for worsening disease during the 3 months prior to\\n     enrollment\",\n",
      "    \"Able to understand and comply with study requirements/procedures (if applicable, with\\n   assistance by caregiver, surrogate, or legally authorized representative) based on the\\n   assessment of the investigator\",\n",
      "    \"Contraceptive use by women should be consistent with local regulations regarding the\\n   methods of contraception for those participating in clinical studies\",\n",
      "    \"Female participants\\n   (a) Women of childbearing potential must:\\n        Have a negative pregnancy test on the day of screening and on Day 1\\n        Use one highly effective form of birth control for at least 28 days prior to Day 1\\n         and agree to continue using one highly effective form of birth control through\\n         60 days following administration of the second dose of study intervention.\\n         A highly effective method of contraception is defined as one that can achieve a\\n         failure rate of less than 1% per year when used consistently and correctly (see\\n         Table 6). Periodic abstinence, the rhythm method, and withdrawal are NOT\\n         acceptable methods of contraception.\",\n",
      "    \"Women are considered of childbearing potential unless they meet either of the\\n      following criteria:\\n        Surgically sterilized (including bilateral tubal ligation, bilateral oophorectomy, or\\n         hysterectomy), or\\n        Post-menopausal\\n           For women aged < 50 years, post-menopausal is defined as having both:\\n            o  A history of ≥ 12 months amenorrhea prior to randomization, without\\n               an alternative cause, following cessation of exogenous sex-hormonal\\n               treatment, and\\n            o  A follicle-stimulating hormone level in the post-menopausal range\\n            Until follicle-stimulating hormone is documented to be within menopausal\\n            range, the participant is to be considered of childbearing potential\\n           For women aged ≥ 50 years, post-menopausal is defined as having a history\\n            of ≥ 12 months amenorrhea prior to randomization, without an alternative\\n            cause, following cessation of exogenous sex-hormonal treatment\",\n",
      "    \"Capable of giving signed informed consent as described in Appendix A, which includes\\n   compliance with the requirements and restrictions listed in the ICF and in this protocol\"\n",
      "  ],\n",
      "  \"exclusion_criteria\": [\n",
      "    \"History of allergy to any component of the vaccine\",\n",
      "    \"History of Guillain-Barré syndrome or any other demyelinating condition\",\n",
      "    \"Significant infection or other acute illness, including fever > 100 °F(> 37.8 °C) on the\\n   day prior to or day of randomization\",\n",
      "    \"History of laboratory-confirmed SARS-CoV-2 infection\",\n",
      "    \"Any confirmed or suspected immunosuppressive or immunodeficient state, including\\n   asplenia\",\n",
      "    \"Recurrent severe infections and use of immunosuppressant medication within the past\\n   6 months (≥ 20 mg per day of prednisone or its equivalent, given daily or on alternate\\n   days for ≥ 15 days within 30 days prior to administration of study intervention)\\n   The following exceptions are permitted:\\n     Topical/inhaled steroids or short-term oral steroids (course lasting ≤ 14 days)\\n     Human immunodeficiency virus-positive stable participants on stable antiretroviral\\n      therapy, eg, (NIH 2020, Waldrop et al 2016)\",\n",
      "    \"History of primary malignancy except for:\\n   (a) Malignancy with low potential risk for recurrence after curative treatment (for\\n      example, history of childhood leukaemia) or metastasis (for example, indolent\\n      prostate cancer) in the opinion of the site investigator.\\n   (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of\\n      disease\\n   (c) Adequately treated uterine cervical carcinoma in situ without evidence of disease\\n   (d) Localized prostate cancer\",\n",
      "    \"Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet\\n   disorder), or prior history of significant bleeding or bruising following IM injections or\\n   venepuncture\",\n",
      "    \"Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal\\n   disease, liver disease, renal disease, endocrine disorder, and neurological illness, as\\n   judged by the Investigator (mild/moderate well-controlled comorbidities are allowed)\",\n",
      "    \"Any other significant disease, disorder, or finding that may significantly increase the risk\\n   to the participant because of participation in the study, affect the ability of the participant\\n   to participate in the study, or impair interpretation of the study data\\n   Note: The AESIs as outlined in AppendixE (including Table 14) should be considered\\n   when evaluating a participant for ExclusionCriterion 10, as the presence of these AESIs,\\n   especially if untreated or uncontrolled, may be a safety risk to the participant, affect the\\n   ability of the participant to participate in the study, or impair interpretation of the study\\n   data. Investigators should review and consider the list of conditions in Appendix F. If any\\n   of these conditions are present in a participant, the Investigator is asked to utilize his/her\\n   clinical judgment in determining the participant’s eligibility for the study. Should the\\n   participant have conditions as outlined in AppendixE and the participant is enrolled, the\\n   Investigator is asked to document notes on site regarding the final rationale for\\n   enrollment.\",\n",
      "    \"Receipt of, or planned receipt of investigational products indicated for the treatment or\\n   prevention of SARS-CoV-2 or COVID-19\\n   Note: For participants who become hospitalized with COVID-19, receipt of licensed\\n   treatment options and/or participation in investigational treatment studies is permitted\",\n",
      "    \"Receipt of any vaccine (licensed or investigational) otherthan licensed influenza vaccines\\n   within 30 days prior to and after administration of study intervention\",\n",
      "    \"Receipt of immunoglobulins and/or any blood products within 3 months prior to\\n   administration of study intervention or expected receipt during the period of study\\n   follow-up\",\n",
      "    \"Involvement in the planning and/or conduct of this study (applies to both Sponsor staff\\n   and/or staff at the study site)\",\n",
      "    \"For women only - currently pregnant (confirmed with positive pregnancy test) or\\n   breast-feeding\",\n",
      "    \"Has donated ≥ 450 mL of blood products within 30 days prior to randomization or\\n   expects to donate blood within 90 days of administration of second dose of study\\n   intervention\"\n",
      "  ]\n",
      "}\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "print(eligibility_output)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
